Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: alzheimer's treatment + future treatment + alzheimer's  Related to the article below (Last Update: 5/12/2008)

Alzheimer's Disease Brings Burdens to Patients and Their Families
RedOrbit, TX -
I try to provide the best care and treatment to the patient and theft loved ones as they go through this terrible disease." The projections for an increase ...
Tales of the unexpected: Medicine's accidental discoveries
Independent, UK -
... and stumbled upon a possible treatment for those with memory problems. Now, the team are applying the same approach to patients with Alzheimer's disease ...
Epix gets $7.5M milestone payment on Alzheimer's treatment
Bizjournals.com, NC - May 5, 2008
Epix Pharmaceuticals Inc. has launched a midstage human clinical trial for a new Alzheimer's treatment, automatically triggering a $7.5 million milestone ...
EPIX Pharmaceuticals Initiates Phase 2b Program in Alzheimer's Disease FOXBusiness
all 33 news articles »  EPIX
Pipex Pharmaceuticals Receives FDA Orphan Drug Designation for ...
CNNMoney.com -
Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic ...PP
Hope amid anguish when Alzheimer's hits home
TheReporter.com, CA - May 11, 2008
What's in the cards, as far as treatment is concerned? There, at least, may be some good news. Many firms have investigational studies in process. ...
Neurobiological Technologies Reports Third Quarter Financial Results
Earthtimes (press release), UK -
... for Age Research that provides us development rights to an exciting compound in early development for the potential treatment of Alzheimer's disease. ...NTII
Pipex Pharmaceuticals Announces Notice of Allowance of US Patent ...
CNNMoney.com - May 7, 2008
11/057.353 containing claims covering the use of thiomolybdates such as oral tetrathiomolybdate (oral TTM) for the treatment of Alzheimer's disease (AD). ...PP
Myriad Genetics Reports Results for Third Quarter of Fiscal 2008
FOXBusiness - May 6, 2008
We have completed the Phase 3 clinical trial of Flurizan(R) in Alzheimer's disease and look forward to announcing the results in the near future. ...MYGN
Allon Data Demonstrate Potential of AL-309 as a New Neuropathy ...
Market Wire (press release) - May 1, 2008
Allon's ADNP compounds AL-108 and AL-208 are now in Phase II clinical trials as treatments for Alzheimer's disease, cognitive impairment associated with ...TSE:NPC
Experimental Alzheimer's Drug Shows Promise
U.S. News & World Report, DC - Apr 17, 2008
That's what remains to be seen." For additional information on current symptom treatment options for Alzheimer's, visit the Alzheimer's Association.
Source: Google News

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the … -
GW Small, PV Rabins, PP Barry, NS Buckholtz, ST … - JAMA, 1997 - Am Med Assoc
... for Geriatric Psychiatry, the Alzheimer's Association, and ... What constitutes safe
and effective treatment for AD ... the most promising questions for future research ...

Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities -
JL Cummings - Neurology, 1998 - AAN Enterprises
... Disease: A Look to the Future Radiology, February 1 ... Education and the Risk of
Alzheimer's Disease: Findings ... lower dose for maintenance treatment is effective Ann ...

… that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers -
MS Mittelman, SH Ferris, G Steinberg, E Shulman, … - The Gerontologist, 1993 - Geron Soc America
... Home page, NEJM Home page R. Mayeux and M. Sano Treatment of Alzheimer's Disease
N ... page, PS Home page EJ Klausner and GS Alexopoulos The Future of Psychosocial ...

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease -
PJ Neumann, RC Hermann, KM Kuntz, SS Araki, SB … - Neurology, 1999 - AAN Enterprises
... Future costs and QALYs are discounted at a 3 ... transition probabilities associated
with a new treatment, we can ... to Establish a Registry for Alzheimer?s Disease ...

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease -
OL Lopez, JT Becker, S Wisniewski, J Saxton, DI … - British Medical Journal, 2002 - jnnp.bmj.com
... a nihilistic view of the palliative treatment of Alzheimer's ... most of the patients
with Alzheimer's disease seen in ... difficult to perform in the future when most ...

… nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment … -
A Seiger, A Nordberg, H von Holst, L Backman, T … - Behav Brain Res, 1993 - ncbi.nlm.nih.gov
Intracranial infusion of purified nerve growth factor to an Alzheimer patient:
the first attempt of a possible future treatment strategy. ...

[CITATION] Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease: A Comparison of Tolerability and … -
A Nordberg, AL Svensson - Drug Safety, 1998
... logical processes of Alzheimer?s disease, there is still no cure for the ... replacement
therapy is one of sev- eral possible treatment strategies; others ...

Cognitive-behavioral interventions for treatment of depression in Alzheimer's patients -
L Teri, D Gallagher-Thompson - The Gerontologist, 1991 - Geron Soc America
... Cognitive-behavioral interventions for treatment of depression ... Memory Stimulation
Programs in Alzheimer's Disease J ... GS Alexopoulos The Future of Psychosocial ...

[PDF] … or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's … -
H Grossman - CNS Spectr, 2003 - alteon.com
... Pathobiology and Future Treatment of ... ALZHEIMER?S DISEASE AND DIABETES MELLITUS: SUMMARY
OF ... 74 Treatment of microglial cultures with peroxisome proliferator ...
-

Current Treatment for Alzheimer Disease and Future Prospects. -
PN Tariot, HJ Federoff - Alzheimer Disease and Associated Disorders, 2003 - alzheimerjournal.com
... Current Treatment for Alzheimer Disease and Future Prospects. [Alzheimer Disease:
Current Challenges, Emerging Treatments: ORIGINAL ARTICLE]. ...

Source: Google Scholar

Future Treatment Of Alzheimer's
A research with experimental rats carried out by the Institute of Neuroscience of the UAB describes the brain region connected to how our declarative memory functions. According to this experiment, part of the prefrontal cortex plays a key role in the social transmission of food preference. This research has helped learn more about how this type of memory functions. In the future, this information could be useful to find new treatment for diseases that affect the memory, such as Alzheimer's disease.

Declarative memory is described as a flexible, conscience and associative type of memory (i.e., it is based on relations between different stimuli). It differs from other types of memories that allow us to recall effective or emotionally-charged data, or carry out processes such as riding a bicycle or playing an instrument. Declarative memory allows us to remember things such as specific moments of our lives, names of people, what we ate for lunch, the capitals of the world, etc. The malfunctioning of this type of memory is one of the most common symptoms found in those suffering from Alzheimer's disease.
A useful model from which to learn about how declarative memory functions is the social transmission of food preference. In other species, this task is connected to the survival of the species and plays a crucial role in their evolution. In this research, the social transmission of food preference was carried out with experimental rats.

When one rodent sniffs another rodent's snout right after the second one has eaten, the first one will later choose to eat the same exact food. Animals learn to remember what their congeners eat and, in that way, lower the risk of eating new foods that could be harmful to them. In addition, they must later use this information acquired during a brief episode of social interaction in very different circumstances. Therefore, they need the flexible expression of memory, which is one of the main traits of declarative memory.

This task depends on learning how to associate smells, a function that is commanded by a specific region of the brain, the nucleus basalis magnocellularis (NBM), which produces acetylcholine (a neurotransmitter that "transfers information" from one neurone to another through synapses). This chemical substance is essential in making the memory work correctly. The nucleus basalis magnocellularis equivalent in humans is the nucleus basalis Meynert. Precisely this is one of the regions of the brain that shown signs of degeneration among those who suffer from Alzheimer's (and who are often treated with drugs that help to produce acetylcholine).

The acetylcholine produced by the nucleus basalis is transferred to other regions of the brain, where it is "recognised" by receptor molecules. The research team examined the possibility of one part of the brain, the prelimbic prefrontal cortex, being linked to the social transmission of food preference. To do so, they applied a chemical compound to the experimental rats that neutralised the acetylcholine receptors (muscarinic cholinergic receptor) of this region. By blocking the receptor, the effect of the neurotransmitter was also neutralised and the changes in the animals' behaviour were observed.

The results demonstrated that the social transmission of food preference was clearly affected after neutralising the acetylcholine receptors. Researchers also verified that the effects were not due to other aspects that could alter the experiment, such as lack of olfactory perception, motivation or social interaction. The results therefore suggest that the prelimbic prefrontal cortex, via the use of acetylcholine, regulates cognitive operations (e.g. flexibility in behaviour, attention or strategic planning) that could be needed to correctly express social transmission of food preference, and therefore necessary for our declarative memory.

Source: Gemma Guillazo
Universitat Autonoma de Barcelona
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.